TY  - JOUR
UR  - https://doi.org/10.3389/fnagi.2022.899158
Y1  - 2022/06/20/
ID  - discovery10153042
N1  - This work is licensed under a Creative Commons Attribution 4.0 International License. The images
or other third-party material in this article are included in the Creative Commons license,
unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license,
users will need to obtain permission from the license holder to reproduce the material. To view a copy of this
license, visit http://creativecommons.org/licenses/by/4.0/
TI  - Depressive Symptoms Have Distinct Relationships With Neuroimaging Biomarkers Across the Alzheimer's Clinical Continuum
VL  - 14
JF  - Frontiers in Aging Neuroscience
PB  - FRONTIERS MEDIA SA
KW  - Science & Technology
KW  -  Life Sciences & Biomedicine
KW  -  Geriatrics & Gerontology
KW  -  Neurosciences
KW  -  Neurosciences & Neurology
KW  -  Alzheimer's disease
KW  -  amyloid deposition
KW  -  cognition
KW  -  depressive symptoms
KW  -  anxiety
KW  -  glucose metabolism
KW  -  subjective cognitive decline
KW  -  gray matter
KW  -  MILD COGNITIVE IMPAIRMENT
KW  -  POSITRON-EMISSION-TOMOGRAPHY
KW  -  SUBJECTIVE MEMORY COMPLAINTS
KW  -  CORTICAL AMYLOID DEPOSITION
KW  -  QUALITY-OF-LIFE
KW  -  NEUROPSYCHIATRIC SYMPTOMS
KW  -  OLDER-ADULTS
KW  -  MATTER HYPOMETABOLISM
KW  -  PSYCHIATRIC-SYMPTOMS
KW  -  BEHAVIORAL SYMPTOMS
N2  - Background: Depressive and anxiety symptoms are frequent in Alzheimer?s disease and associated with increased risk of developing Alzheimer?s disease in older adults. We sought to examine their relationships to Alzheimer?s disease biomarkers across the preclinical and clinical stages of the disease. Method: Fifty-six healthy controls, 35 patients with subjective cognitive decline and 56 amyloid-positive cognitively impaired patients on the Alzheimer?s continuum completed depression and anxiety questionnaires, neuropsychological tests and neuroimaging assessments. We performed multiple regressions in each group separately to assess within group associations of depressive and anxiety symptoms with either cognition (global cognition and episodic memory) or neuroimaging data (gray matter volume, glucose metabolism and amyloid load). Results: Depressive symptoms, but not anxiety, were higher in patients with subjective cognitive decline and cognitively impaired patients on the Alzheimer?s continuum compared to healthy controls. Greater depressive symptoms were associated with higher amyloid load in subjective cognitive decline patients, while they were related to higher cognition and glucose metabolism, and to better awareness of cognitive difficulties, in cognitively impaired patients on the Alzheimer?s continuum. In contrast, anxiety symptoms were not associated with brain integrity in any group. Conclusion: These data show that more depressive symptoms are associated with greater Alzheimer?s disease biomarkers in subjective cognitive decline patients, while they reflect better cognitive deficit awareness in cognitively impaired patients on the Alzheimer?s continuum. Our findings highlight the relevance of assessing and treating depressive symptoms in the preclinical stages of Alzheimer?s disease.
A1  - Moulinet, Ines
A1  - Touron, Edelweiss
A1  - Mezenge, Florence
A1  - Dautricourt, Sophie
A1  - de la Sayette, Vincent
A1  - Vivien, Denis
A1  - Marchant, Natalie L
A1  - Poisnel, Geraldine
A1  - Chetelat, Gael
EP  - 12
AV  - public
ER  -